Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 9 (4), 879-85

Synergistic Interaction Between Highly Specific cyclooxygenase-2 Inhibitor, MF-tricyclic and Lovastatin in Murine Colorectal Cancer Cell Lines

Affiliations
  • PMID: 12066226

Synergistic Interaction Between Highly Specific cyclooxygenase-2 Inhibitor, MF-tricyclic and Lovastatin in Murine Colorectal Cancer Cell Lines

Wojciech Feleszko et al. Oncol Rep.

Abstract

Statins, anti-hypercholesterolemic agents, have previously been reported to induce apoptosis and exert antitumor activity when combined with other antitumor agents. The potential of lovastatin in combination with highly specific COX-2 inhibitor (MF-tricyclic) to induce anti-proliferative activity against tumour cells was evaluated using the combination index (CI) method. Murine colorectal cancer (colon-26, CMT-93), melanoma (B16F10) and human bladder carcinoma cells (T24) were tested. Exposure of colon-26 and CMT-93 cells resulted in synergistic interactions in both cell lines with CI<1 for 20-80% inhibition of cell growth in both cell lines. This synergy was not observed in the B16F10 melanoma and T24 bladder carcinoma cells. MF-tricyclic (40 microg/ml), augmented lovastatin-induced apoptosis up to 2.5-fold in colon-26 cancer cells. Combination of a specific COX-2 inhibitor, MF-tricyclic, may increase antiproliferative effects of lovastatin in colon cancer cells and this effect was due to an augmented apoptosis.

Similar articles

See all similar articles

Cited by 3 articles

Publication types

MeSH terms

Feedback